You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
Several disputes between clinical researchers and pharmaceutical manufacturers have highlighted the critical importance of protecting the right of trial subjects to disclosure of risks and the academic freedom of investigators. In this Policy Forum, some lessons from an inquiry into the case involving Dr. Nancy Olivieri, Apotex Inc., the Hospital for Sick Children, and the University of Toronto are outlined. Given that pharmaceutical companies are more powerful than individual researchers, it is essential that institutions live up to their responsibilities to protect the public interest by ensuring they have robust policies and practices in place governing disclosure of risks and academic independence.
